Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Etoposide 2Cisplatin 2osimertinib 1apatinib 1S 1 (combination) 1PE regimen 1Docetaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Progression Free Survival × Clear all
NCT03769935 2023-03-29

Maintenance Therapy for Small-cell Lung Cancer

Qingdao Central Hospital

Phase 2 Completed
90 enrolled

Progression Free Survival

NCT02959749 2018-02-14

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2/3 Completed
147 enrolled

Progression Free Survival

NCT03100955 2017-04-04

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Qingdao University

Phase 3 Unknown
120 enrolled

Progression Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡